Literature DB >> 10725645

A Comparison of clinical target volumes determined by CT and MRI for the radiotherapy planning of base of skull meningiomas.

V S Khoo1, E J Adams, F Saran, J L Bedford, J R Perks, A P Warrington, M Brada.   

Abstract

PURPOSE: To assess the utility of image registration and to compare the localization of clinical target volumes (CTV) using CT and MRI for patients with base of skull meningiomas undergoing radiotherapy. METHODS AND MATERIALS: Seven patients were imaged using CT and a T1-weighted MR volumetric sequence. Following image registration using a chamfer-matching algorithm, transaxial MR slices were reconstructed to match the planning CT slices. The accuracy of the image fusion was assessed in a preliminary study with matching accuracy better than 1.5 mm. The CTV in each patient was separately segmented by two independent observers for both CT and reconstructed MR image sets. Scalar and vector assessments were made of the difference in radial extent between the two outlines on each transaxial plane for all patients. A positive vector value corresponded to a greater extension of the tumor on MR compared to CT and vice versa. Scalar measurements compared the modulus of the differences between MR and CT, regardless of which volume was more extensive. Qualitative comparisons were also performed.
RESULTS: Interobserver difference was small with a mean (+/- 1SD) volume difference of 1.5 +/- 1.5 cm(3) for CT and 0.5 +/- 1.0 cm(3) for MRI. The mean CT- and MR- CTVs were 17.6 +/-10.8 and 19.6 +/-14.2 cm(3) respectively. The mean overlap and composite volumes were 13.8 +/-10. 1 and 23.3 +/-14.8 cm(3) respectively. Average scalar differences in the left, right, anterior, and posterior directions were 6.0 +/- 7.0, 3.3 +/- 2.5, 4.9 +/- 3.9, and 4.5 +/- 5.0 mm respectively. The average vector differences were 3.3 +/- 8.5, -0.3 +/- 3.8, 1.1 +/- 5. 8, 1.5 +/- 6.4 mm (for left, right, anterior, and posterior directions respectively). Qualitatively, MR appeared to discern more tumor involvement in soft tissue regions adjacent to the skull base whereas CT appeared to provide larger target volumes within bony regions.
CONCLUSIONS: MRI appeared to define CTVs that were larger but not inclusive of CT-defined CTVs. Although the average vector differences were small, the differences on individual borders could be large. In some instances, the CT or MR volumes were vastly different, each providing separate information. Therefore, the use of MRI and CT is complementary. Until accurate histological confirmation of disease extent is available, it is prudent to consider composite CT/MR volumes for the radiotherapy planning of base of skull meningiomas.

Entities:  

Mesh:

Year:  2000        PMID: 10725645     DOI: 10.1016/s0360-3016(99)00541-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.

Authors:  Habib Zaidi; Issam El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

2.  The influence of MRI scan position on image registration accuracy, target delineation and calculated dose in prostatic radiotherapy.

Authors:  S Hanvey; A H Sadozye; M McJury; M Glegg; J Foster
Journal:  Br J Radiol       Date:  2012-12       Impact factor: 3.039

3.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  CT- and MRI-based gross target volume comparison in vestibular schwannomas.

Authors:  Bhudevi Soubhagya N Kulkarni; Harjot Bajwa; Mukka Chandrashekhar; Sunil Dutt Sharma; Rohith Singareddy; Dileep Gudipudi; Shabbir Ahmad; Alok Kumar; N V N Madusudan Sresty; Alluri Krishnam Raju
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-22

5.  Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas.

Authors:  Fonyuy Nyuyki; Michail Plotkin; Reinhold Graf; Roger Michel; Ingo Steffen; Timm Denecke; Lilli Geworski; Daniel Fahdt; Winfried Brenner; Reinhard Wurm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-18       Impact factor: 9.236

6.  Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy--a case series.

Authors:  Reinhold Graf; Michail Plotkin; Ingo G Steffen; Reinhard Wurm; Peter Wust; Winfried Brenner; Volker Budach; Harun Badakhshi
Journal:  Head Face Med       Date:  2012-01-04       Impact factor: 2.151

7.  Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study.

Authors:  Karen Buch; Tye Morancy; Irving Kaplan; Muhammad M Qureshi; Ariel E Hirsch; Neil M Rofksy; Edward Holupka; Renee Oismueller; Robert Hawliczek; Thomas H Helbich; B Nicolas Bloch
Journal:  J Contemp Brachytherapy       Date:  2014-10-28

8.  MRI Reduces Variation of Contouring for Boost Clinical Target Volume in Breast Cancer Patients Without Surgical Clips in the Tumour Bed.

Authors:  Noora Al-Hammadi; Palmira Caparrotti; Saju Divakar; Mohamed Riyas; Suparna Halsnad Chandramouli; Rabih Hammoud; Jillian Hayes; Maeve Mc Garry; Satheesh Prasad Paloor; Primoz Petric
Journal:  Radiol Oncol       Date:  2017-03-17       Impact factor: 2.991

9.  The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy.

Authors:  Scott Hanvey; Mark McJury; Lye Mun Tho; Martin Glegg; Maureen Thomson; Derek Grose; Allan James; Mohammed Rizwanullah; Claire Paterson; John Foster
Journal:  Radiat Oncol       Date:  2013-05-28       Impact factor: 3.481

10.  Multimodality image fusion in dose escalation studies of brain tumors.

Authors:  D Rajasekar; N R Datta; R K Gupta; P K Pradhan; S Ayyagari
Journal:  J Appl Clin Med Phys       Date:  2003       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.